Hong Kong Pharmaceuticals Stock News

People's Insurance Company (Group) of China (SEHK:1339) has been thrust into focus after chairperson Ms. Ding Xiangqun resigned due to a job transfer. She is stepping down from several key board and committee roles. See our latest analysis for People's Insurance Company (Group) of China. The leadership change lands against a mixed backdrop, with the current share price at HK$5.26, a 7 day share price return of 3.95% and a year to date share price return down 24.86%. At the same time, the 5...

Texwinca Holdings (SEHK:321) has just reported FY 2026 first half revenue of HK$2.7b and basic EPS of HK$0.08, with trailing twelve month EPS at HK$0.12 and revenue at HK$5.1b setting the overall earnings backdrop. Over recent halves the company has seen revenue move from HK$3.0b and EPS of HK$0.07 in 1H FY 2025 to HK$2.6b and EPS of HK$0.01 in 2H FY 2025, before landing at the latest HK$2.7b and HK$0.08 print. This feeds into trailing earnings growth of 38.4% and a 3.1% net margin. For...

Recent share performance and business snapshot JF SmartInvest Holdings (SEHK:9636) has drawn attention after a sharp pullback, with the stock down 33% over the past month and 23% over the past 3 months, prompting closer scrutiny of its fundamentals. The company operates as an online financial information provider in the People’s Republic of China, offering market data processing, investment decision support tools, cloud charting, investor education content, and livestreamed market commentary...

Kingsoft (SEHK:3888) has cut its final dividend to HK$0.13 per share for 2025, while also approving a new Memorandum and Articles at its 28 May 2026 annual general meeting, reshaping its shareholder framework. See our latest analysis for Kingsoft. Despite the dividend cut and refreshed governance framework, the share price has been volatile. The 7 day share price return is 9.30%, but the year to date share price return is down 16.24%, while the 1 year total shareholder return has fallen...

J&T Global Express (SEHK:1519) has just been added to the Hang Seng Index, drawing fresh attention to the stock as index-tracking investors reassess its role in Hong Kong portfolios. See our latest analysis for J&T Global Express. Despite the Hang Seng inclusion and the recent private placement involving SF Holdings Group, the stock has been weak in recent months, with a 30 day share price return down 8.25% and year to date share price return down 15.56%. However, the 1 year total shareholder...

As global markets navigate a complex landscape of economic indicators and geopolitical tensions, investors are increasingly turning their attention to the opportunities within Asian equities. Penny stocks, despite their somewhat antiquated name, continue to attract interest due to their potential for significant value appreciation. By focusing on companies with strong financial foundations and growth potential, investors can uncover promising opportunities among these smaller or newer market...

As global markets experience volatility, with mixed performances across major indices and economic data highlighting resilience amidst inflationary pressures, investors are increasingly looking towards Asia for opportunities in dividend stocks. In such an environment, a good dividend stock is often characterized by its ability to provide consistent returns through stable payouts, even as broader market conditions fluctuate.

At its annual general meeting on May 29, 2026, Xinyi Solar Holdings Limited obtained shareholder approval to declare and pay a final dividend of HK$0.008 per share for the year ended December 31, 2025. This dividend decision highlights how the company is choosing to return cash to shareholders while signaling its current capital allocation priorities. We will now examine how the approved final dividend shapes Xinyi Solar Holdings' investment narrative and what it may imply for investors. The...

In early June 2026, Innovent Biologics presented new clinical and preclinical data across its obesity and metabolic pipeline at the American Diabetes Association Scientific Sessions, including first-in-human results for its oral GLP-1 receptor agonist IBI3032 and updates on mazdutide and other next-generation candidates. A distinctive angle for investors is Innovent’s push into true oral and once-weekly small-molecule GLP-1 therapies, aiming to combine low-dose efficacy with improved...

China Communications Services (SEHK:552) is back in focus after shareholders approved a final dividend and a broad share issuance mandate at the recent Annual General Meeting, alongside an executive reshuffle in senior management. See our latest analysis for China Communications Services. Despite the recent AGM approvals and executive changes, the share price is at HK$4.33 after a 5.35% 1 day share price return. The 1 year total shareholder return of 5.04% reflects steadier long term gains,...

Insiders who bought CN¥17.0m worth of Starjoy Wellness and Travel Company Limited ( HKG:3662 ) stock in the last year...

It looks like China Resources Mixc Lifestyle Services Limited ( HKG:1209 ) is about to go ex-dividend in the next 4...

Investors are often guided by the idea of discovering 'the next big thing', even if that means buying 'story stocks...

Investors who take an interest in EuroEyes International Eye Clinic Limited ( HKG:1846 ) should definitely note that...

3SBio Inc. ( HKG:1530 ) shareholders (or potential shareholders) will be happy to see that the Co-Founder, Jing Lou...

Just because a business does not make any money, does not mean that the stock will go down. Indeed, Asia Energy...

Readers hoping to buy China Resources Land Limited ( HKG:1109 ) for its dividend will need to make their move shortly...

Recent trading performance and business snapshot With no single headline event driving trading, Beijing Geekplus Technology (SEHK:2590) has drawn attention after the stock fell 5.4% in the latest session and is down 31% over the past month. That weak price action sits alongside reported annual revenue of CN¥3,171.0 million and net income of CN¥25.5 million, as the company focuses on robotics products and solutions across Mainland China, the United States, Europe, and the Asia Pacific. See our...

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

Arta TechFin Corporation Limited's (HKG:279) value has fallen 12% in the last week, but insiders who sold HK$216m worth...

As Asian markets navigate a landscape of mixed economic signals and geopolitical tensions, investors are increasingly drawn to the potential stability offered by dividend stocks. In this environment, a good stock is often characterized by its ability to provide consistent income through dividends, which can be particularly appealing amid fluctuating market conditions.

As global markets navigate mixed signals from economic indicators and geopolitical tensions, the Asian tech sector presents intriguing opportunities for investors, particularly in light of China's AI advancements and Japan's cautious monetary policy outlook. In this environment, identifying high-growth tech stocks with innovative capabilities and resilience to market fluctuations can be crucial for potential long-term success.

Global New Material International Holdings (SEHK:6616) is back in focus after its German subsidiary Susonity announced a two phase price increase on pigment products to address rising input costs across automotive, cosmetic, and industrial segments. See our latest analysis for Global New Material International Holdings. The pricing move comes after a weaker run in the stock, with a 30 day share price return down 17.41% and the year to date share price return down 28.15%. However, the 1 year...

Hansoh Pharmaceutical Group added to Hang Seng China Enterprises Index Hansoh Pharmaceutical Group (SEHK:3692) has been added to the Hang Seng China Enterprises Index, a move that increases the stock’s visibility and may influence flows from index-linked funds. See our latest analysis for Hansoh Pharmaceutical Group. Alongside the index inclusion, Hansoh Pharmaceutical Group’s share price has been under pressure recently. It has a 30 day share price return of down 20.12% and a year to date...